Industrial Transformation Research Hubs - Grant ID: IH150100028
Funder
Australian Research Council
Funding Amount
$3,708,510.00
Summary
ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecu ....ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecules. The initial focus would be early diagnosis of disease and point-of-care drug testing for humans and animals, but the technology platform could be used to sample food and environmental toxins. The hub expects these disruptive technologies will make Australian biotechnology, diagnostics, veterinary, agribusiness and manufacturing firms globally competitive.Read moreRead less
Nanosampling sensors for real-time embryo monitoring. The health potential of every individual is established early in life, during the period when the oocytes mature and embryos are formed. This project will develop a photonic sensing platform capable of monitoring embryos as they develop, which will lead to new insight into the earliest stages of life and improved assisted reproduction technologies.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE150100177
Funder
Australian Research Council
Funding Amount
$440,000.00
Summary
National Live Cell Scanning Platform for Nanoparticle Tracking. National live cell scanning platform for nanoparticle tracking: The aim of the project is to establish a multi-disciplinary, multi-user, self-correlated scanning facility to reach a new level of temporal and spatial precision for real-time tracking and quantification of biomolecules and nanoparticles within large populations of living cells. The facility will consist of a live-cell spinning-disc confocal microscope, a correlated bio ....National Live Cell Scanning Platform for Nanoparticle Tracking. National live cell scanning platform for nanoparticle tracking: The aim of the project is to establish a multi-disciplinary, multi-user, self-correlated scanning facility to reach a new level of temporal and spatial precision for real-time tracking and quantification of biomolecules and nanoparticles within large populations of living cells. The facility will consist of a live-cell spinning-disc confocal microscope, a correlated biological atomic force microscope, and remote access facilities. It is expected that with superior optical characterisation and mechanical manipulation, the automated orthogonal scanning facility will open new avenues to reveal unprecedented information from biological and pathological processes. The collaborative facility will support world-class researchers in the multi-disciplinary areas of physical, material and life sciences, placing Australia at the forefront of nanoscale biophotonics.Read moreRead less
Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and h ....Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and hence the risks of dose related side effects. This project has potential both to improve healthcare and to encourage the growth of expertise in the biotechnology industry in Australia.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC190100026
Funder
Australian Research Council
Funding Amount
$4,969,663.00
Summary
ARC Training Centre for Cell and Tissue Engineering Technologies. The ARC Training Centre for Cell and Tissue Engineering Technologies aims to provide training to create a highly skilled workforce for the tissue engineering and regenerative medicine sector and to enhance research performance and innovation in Australia through fundamental and applied research carried out in industry-led PhD projects. The research aims to address major aspects of the manufacturing and commercialisation pathway an ....ARC Training Centre for Cell and Tissue Engineering Technologies. The ARC Training Centre for Cell and Tissue Engineering Technologies aims to provide training to create a highly skilled workforce for the tissue engineering and regenerative medicine sector and to enhance research performance and innovation in Australia through fundamental and applied research carried out in industry-led PhD projects. The research aims to address major aspects of the manufacturing and commercialisation pathway and barriers faced by the sector, namely improving process efficiencies, enabling early-stage scale-up (cell/tissue) and development of the sector's supply chain. The knowledge created and research undertaken would help to accelerate commercialisation in regenerative medicine, tissue engineering and cell therapies.Read moreRead less
Bio-MEMS eye sensor for continuous monitoring of intraocular pressure. Glaucoma is a leading cause of preventable blindness, particularly prevalent in the 60+ population, caused by elevated intraocular pressure (IOP). Current treatment to monitor and prevent glaucoma-related blindness is by lowering IOP with eye-drops, laser therapy or surgery. This project directly benefits our aging population by ensuring independence and quality of life, whilst reducing long-term medical and social costs. By ....Bio-MEMS eye sensor for continuous monitoring of intraocular pressure. Glaucoma is a leading cause of preventable blindness, particularly prevalent in the 60+ population, caused by elevated intraocular pressure (IOP). Current treatment to monitor and prevent glaucoma-related blindness is by lowering IOP with eye-drops, laser therapy or surgery. This project directly benefits our aging population by ensuring independence and quality of life, whilst reducing long-term medical and social costs. By incorporating nanotechnology with ophthalmology we will provide an economic solution to long-term, reliable, home-monitoring of IOP. An implantable IOP sensor, will identify patients requiring more invasive treatment compared with those with less aggressive disease, leading to better health resource utilisation.Read moreRead less
New uses for milk-derived products for eradication of Helicobacter pylori infection and gastro-intestinal site-specific delivery of active agents. Helicobacter pylori is the most significant bacterial pathogen in the world, infecting 50% globally. Current treatments are inducing rapid antibiotic resistance and are thus becoming increasingly less effective. The infection is acquired in childhood and new methods to prevent and/or treat the infection, minimising acquisition of antibiotic resistance ....New uses for milk-derived products for eradication of Helicobacter pylori infection and gastro-intestinal site-specific delivery of active agents. Helicobacter pylori is the most significant bacterial pathogen in the world, infecting 50% globally. Current treatments are inducing rapid antibiotic resistance and are thus becoming increasingly less effective. The infection is acquired in childhood and new methods to prevent and/or treat the infection, minimising acquisition of antibiotic resistance are urgently required. This project seeks to develop new ways of doing this that combine novel antibacterials with techniques to deliver them (and monitor this delivery) as well as modify the complex protective habitat in the stomach.Read moreRead less
Improving and manipulating the immune adjuvant properties of recombinant fowlpox vectors. Unbalanced immune responses may cause or worsen common and important diseases such as infections, allergies, cancers and autoimmunity. Interleukin-4 (IL-4) is the only immune active product or cytokine that safely skews an aberrant immune response to a healing type of response. Fowlpox viruses (FPV) provide safe and effective human vaccines. Engineering FPV to make both a relevant antigen and a cytokine is ....Improving and manipulating the immune adjuvant properties of recombinant fowlpox vectors. Unbalanced immune responses may cause or worsen common and important diseases such as infections, allergies, cancers and autoimmunity. Interleukin-4 (IL-4) is the only immune active product or cytokine that safely skews an aberrant immune response to a healing type of response. Fowlpox viruses (FPV) provide safe and effective human vaccines. Engineering FPV to make both a relevant antigen and a cytokine is proprietary technology. With our commercial partner and using experimental mice, we will test the concept that FPV making a model antigen and IL-4 initiate and/or maintain beneficial Type 2 responses. A successful outcome will guide clinical FPV-based vaccine development for the treatment of important human and veterinary diseases.Read moreRead less
Attachment of Growth Factors to Pure, Plasma Modified and Coated Titanium Substrates. Titanium and its alloys are routinely used as medical and dental implants. Despite coating with hydroxyapatite, a material well known to improve implant fixation, many such implants fail because of lack of strong integration with bone. This proposal aims at achieving long-term stability of titanium implants through their surface modification and subsequent attachment of growth factors. The use of latter has alr ....Attachment of Growth Factors to Pure, Plasma Modified and Coated Titanium Substrates. Titanium and its alloys are routinely used as medical and dental implants. Despite coating with hydroxyapatite, a material well known to improve implant fixation, many such implants fail because of lack of strong integration with bone. This proposal aims at achieving long-term stability of titanium implants through their surface modification and subsequent attachment of growth factors. The use of latter has already been shown to help bone-implant integration. Successful project implementation will provide titanium implant surfaces that will help achieve speedier and improved implant fixation with long-term stability. Knowledge, expertise and techniques developed will help the industry partner expanding its research base and business and generating wealth in Australia. Training of world-class research students in the emerging field of biotechnology will be another major outcome.Read moreRead less